These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9592931)

  • 1. [3D QSAR analysis of novel 5-HT1A receptor ligands].
    Borosy AP
    Acta Pharm Hung; 1998 Mar; 68(2):71-8. PubMed ID: 9592931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
    Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
    J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models.
    Gaillard P; Carrupt PA; Testa B; Schambel P
    J Med Chem; 1996 Jan; 39(1):126-34. PubMed ID: 8568799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-dimensional quantitative structure-activity relationship study of nonsteroidal estrogen receptor ligands using the comparative molecular field analysis/cross-validated r2-guided region selection approach.
    Sadler BR; Cho SJ; Ishaq KS; Chae K; Korach KS
    J Med Chem; 1998 Jun; 41(13):2261-7. PubMed ID: 9632359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arylpiperazines with serotonin-3 antagonist activity: a comparative molecular field analysis.
    Morreale A; Gálvez-Ruano E; Iriepa-Canalda I; Boyd DB
    J Med Chem; 1998 Jun; 41(12):2029-39. PubMed ID: 9622544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theoretical models of interactions between buspirone analogues and 5-HT1A and 5-HT2A serotonin receptor subtypes.
    Bronowska A; Sylte I; Edvardsen Ø; Østensen R; Leś A; Chilmonczyk Z
    Acta Pol Pharm; 2000 Nov; 57 Suppl():40-5. PubMed ID: 11293260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
    Hou T; Zhu L; Chen L; Xu X
    J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative molecular field analysis (CoMFA) study using semiempirical, density functional, ab initio methods and pharmacophore derivation using DISCOtech on sigma 1 ligands.
    Jung D; Floyd J; Gund TM
    J Comput Chem; 2004 Aug; 25(11):1385-99. PubMed ID: 15185333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based 3D-QSAR studies on heteroarylpiperazine derivatives as 5-HT3 receptor antagonists.
    Zhou YJ; Zhu LP; Tang Y; Ye DY
    Eur J Med Chem; 2007 Jul; 42(7):977-84. PubMed ID: 17331624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore-based 3D QSAR studies on a series of high affinity 5-HT1A receptor ligands.
    Weber KC; Salum LB; Honório KM; Andricopulo AD; da Silva AB
    Eur J Med Chem; 2010 Apr; 45(4):1508-14. PubMed ID: 20133028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and structure-activity relationships of a new model of arylpiperazines. 4. 1-[omega-(4-Arylpiperazin-1-yl)alkyl]-3-(diphenylmethylene) - 2, 5-pyrrolidinediones and -3-(9H-fluoren-9-ylidene)-2, 5-pyrrolidinediones: study of the steric requirements of the terminal amide fragment on 5-HT1A affinity/selectivity.
    López-Rodríguez ML; Morcillo MJ; Rovat TK; Fernández E; Vicente B; Sanz AM; Hernández M; Orensanz L
    J Med Chem; 1999 Jan; 42(1):36-49. PubMed ID: 9888831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
    Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C; Kleven M
    J Med Chem; 1999 May; 42(9):1648-60. PubMed ID: 10229633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study.
    Mor M; Rivara S; Silva C; Bordi F; Plazzi PV; Spadoni G; Diamantini G; Balsamini C; Tarzia G; Fraschini F; Lucini V; Nonno R; Stankov BM
    J Med Chem; 1998 Sep; 41(20):3831-44. PubMed ID: 9748358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D QSAR comparative molecular field analysis on nonsteroidal farnesoid X receptor activators.
    Honório KM; Garratt RC; Polikarpov I; Andricopulo AD
    J Mol Graph Model; 2007 Mar; 25(6):921-7. PubMed ID: 17055759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of a series of 6-substituted-2-pyridinylmethylamine derivatives as novel, high-affinity, selective agonists at 5-HT1A receptors.
    Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C
    J Med Chem; 1998 Dec; 41(25):5070-83. PubMed ID: 9836623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QSAR study of a large set of 3-pyridyl ethers as ligands of the alpha4beta2 nicotinic acetylcholine receptor.
    Zhang H; Li H; Ma Q
    J Mol Graph Model; 2007 Jul; 26(1):226-35. PubMed ID: 17208024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CoMFA, CoMSIA, and molecular hologram QSAR studies of novel neuronal nAChRs ligands-open ring analogues of 3-pyridyl ether.
    Zhang H; Li H; Liu C
    J Chem Inf Model; 2005; 45(2):440-8. PubMed ID: 15807510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of validated QSAR models of D1 dopaminergic antagonists for database mining.
    Oloff S; Mailman RB; Tropsha A
    J Med Chem; 2005 Nov; 48(23):7322-32. PubMed ID: 16279792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines at five recombinant GABAA/benzodiazepine receptor subtypes [alphaxbeta3gamma2 (x = 1-3, 5, and 6)] via comparative molecular field analysis.
    Huang Q; Liu R; Zhang P; He X; McKernan R; Gan T; Bennett DW; Cook JM
    J Med Chem; 1998 Oct; 41(21):4130-42. PubMed ID: 9767648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.